DE69730217D1 - Dha-pharmazeutisches produkt konjugate - Google Patents

Dha-pharmazeutisches produkt konjugate

Info

Publication number: DE69730217D1
Authority: DE; Germany
Prior art keywords: dha; pharmaceutical product; product conjugate; pharmaceutical agents; conjugate
Prior art date: 1996-05-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69730217T

Other languages

English (en)

Other versions

DE69730217T2 (de

Inventor

O Bradley

E Shashoua

L Webb

S Swindell

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

American Regent Inc

Original Assignee

Protarga Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-22

Filing date

1997-05-22

Publication date

2004-09-16

1997-05-22 Application filed by Protarga Inc filed Critical Protarga Inc

2004-09-16 Publication of DE69730217D1 publication Critical patent/DE69730217D1/de

2005-07-28 Application granted granted Critical

2005-07-28 Publication of DE69730217T2 publication Critical patent/DE69730217T2/de

2017-05-23 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

DE69730217T 1996-05-22 1997-05-22 Dha-pharmazeutisches produkt konjugate Expired - Lifetime DE69730217T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/651,312 US5795909A (en)	1996-05-22	1996-05-22	DHA-pharmaceutical agent conjugates of taxanes
US651312		1996-05-22
PCT/US1997/008867 WO1997044063A2 (en)	1996-05-22	1997-05-22	Dha-pharmaceutical agent conjugates

Publications (2)

Publication Number	Publication Date
DE69730217D1 true DE69730217D1 (de)	2004-09-16
DE69730217T2 DE69730217T2 (de)	2005-07-28

Family

ID=24612392

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69730217T Expired - Lifetime DE69730217T2 (de)	1996-05-22	1997-05-22	Dha-pharmazeutisches produkt konjugate

Country Status (10)

Country	Link
US (3)	US5795909A (de)
EP (2)	EP0909183B1 (de)
JP (1)	JP4402173B2 (de)
AT (1)	ATE273025T1 (de)
AU (1)	AU725759B2 (de)
CA (1)	CA2255614C (de)
DE (1)	DE69730217T2 (de)
DK (1)	DK0909183T3 (de)
ES (1)	ES2222514T3 (de)
WO (1)	WO1997044063A2 (de)

Families Citing this family (253)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5994392A (en)	1988-02-26	1999-11-30	Neuromedica, Inc.	Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US20030068362A1 (en) *	1993-02-22	2003-04-10	American Bioscience, Inc.	Methods and formulations for the delivery of pharmacologically active agents
US5439686A (en) *	1993-02-22	1995-08-08	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20030133955A1 (en) *	1993-02-22	2003-07-17	American Bioscience, Inc.	Methods and compositions useful for administration of chemotherapeutic agents
US20030073642A1 (en) *	1993-02-22	2003-04-17	American Bioscience, Inc.	Methods and formulations for delivery of pharmacologically active agents
US5972948A (en) *	1994-07-01	1999-10-26	Solvay Pharmaceuticals Gmbh	Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
US6231888B1 (en)	1996-01-18	2001-05-15	Perio Products Ltd.	Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US6576636B2 (en)	1996-05-22	2003-06-10	Protarga, Inc.	Method of treating a liver disorder with fatty acid-antiviral agent conjugates
WO1997044026A1 (en) *	1996-05-22	1997-11-27	Neuromedica, Inc.	Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US5795909A (en) *	1996-05-22	1998-08-18	Neuromedica, Inc.	DHA-pharmaceutical agent conjugates of taxanes
KR100330373B1 (ko) *	1996-05-28	2002-11-07	주식회사한국신약	탁솔을 함유한 주사용 약제 조성물
US6440980B1 (en) *	1996-09-17	2002-08-27	Avanir Pharmaceuticals	Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
KR20010012809A (ko) *	1997-05-21	2001-02-26	더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티	생체막을 통한 수송을 증진시키는 조성물 및 방법
US8853260B2 (en) *	1997-06-27	2014-10-07	Abraxis Bioscience, Llc	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
ZA986614B (en) *	1997-07-25	1999-01-27	Gilead Sciences	Nucleotide analog composition
DE69834937D1 (de)	1997-09-17	2006-07-27	Eisai Co Ltd	Antibiotika zur behandlung von magengeschwuren
US20030095926A1 (en) *	1997-10-01	2003-05-22	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20040136915A1 (en) *	1997-10-01	2004-07-15	Dugger Harry A.	Buccal, polar and non-polar spray containing atropine
US20030190286A1 (en) *	1997-10-01	2003-10-09	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
AU4894697A (en) *	1997-10-01	1999-04-23	Flemington Pharmaceutical Corporation	Buccal, polar and non-polar spray or capsule
US20030077227A1 (en) *	1997-10-01	2003-04-24	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030082107A1 (en) *	1997-10-01	2003-05-01	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20040141923A1 (en) *	1997-10-01	2004-07-22	Dugger Harry A.	Buccal, polar and non-polar spray containing alprazolam
US20040136913A1 (en) *	1997-10-01	2004-07-15	Dugger Harry A.	Buccal, polar and non-polar spray containing sumatriptan
US20050180923A1 (en) *	1997-10-01	2005-08-18	Dugger Harry A.Iii	Buccal, polar and non-polar spray containing testosterone
US20050002867A1 (en) *	1997-10-01	2005-01-06	Novadel Pharma Inc.	Buccal, polar and non-polar sprays containing propofol
US20030095927A1 (en) *	1997-10-01	2003-05-22	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20090162300A1 (en) *	1997-10-01	2009-06-25	Dugger Iii Harry A	Buccal, polar and non-polar spray containing alprazolam
US20030077229A1 (en) *	1997-10-01	2003-04-24	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20050163719A1 (en) *	1997-10-01	2005-07-28	Dugger Harry A.Iii	Buccal, polar and non-polar spray containing diazepam
US20050281752A1 (en) *	1997-10-01	2005-12-22	Dugger Harry A Iii	Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US7632517B2 (en) *	1997-10-01	2009-12-15	Novadel Pharma Inc.	Buccal, polar and non-polar spray containing zolpidem
US20050287075A1 (en) *	1997-10-01	2005-12-29	Dugger Harry A Iii	Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030077228A1 (en) *	1997-10-01	2003-04-24	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20030095925A1 (en) *	1997-10-01	2003-05-22	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20040136914A1 (en)	1997-10-01	2004-07-15	Dugger Harry A.	Buccal, polar and non-polar spray containing ondansetron
US20030185761A1 (en) *	1997-10-01	2003-10-02	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US5977174A (en) *	1997-11-26	1999-11-02	Neuromedica, Inc.	Cholinergic compositions and uses thereof
US5955459A (en) *	1997-11-26	1999-09-21	Neuromedica, Inc.	Fatty acid-antipsychotic compositions and uses thereof
US6153653A (en) *	1997-11-26	2000-11-28	Protarga, Inc.	Choline compositions and uses thereof
US6197764B1 (en)	1997-11-26	2001-03-06	Protarga, Inc.	Clozapine compositions and uses thereof
KR20000076105A (ko) *	1998-01-13	2000-12-26	도리이 신이찌로	항생제를 함유한 국소 투여용 항균 조성물
US6958148B1 (en) *	1998-01-20	2005-10-25	Pericor Science, Inc.	Linkage of agents to body tissue using microparticles and transglutaminase
UA65607C2 (uk)	1998-03-04	2004-04-15	Орто-Макнейл Фармацевтикал, Інк.	Фармацевтична композиція (варіанти) та спосіб її приготування
FI980901A (fi) *	1998-04-23	1999-10-24	Orion Yhtymae Oyj	Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
ATE348601T1 (de) *	1998-05-18	2007-01-15	Takeda Pharmaceutical	Im munde zerfallende tablette enthaltend ein benzimidazole
US7413759B2 (en) *	1998-05-21	2008-08-19	Beech-Nut Nutrition Corporation	Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
AU763309B2 (en) *	1998-07-20	2003-07-17	Smithkline Beecham Corporation	Bioenhanced formulations comprising eprosartan in oral solid dosage form
ES2347968T3 (es) *	1998-07-28	2010-11-26	Takeda Pharmaceutical Company Limited	Preparacion solida que se disgrega rapidamente.
CA2334120C (en) *	1998-08-10	2006-10-17	Asahi Kasei Kogyo Kabushiki Kaisha	Oral sustained-release preparation of fasudil hydrochloride
US20080213378A1 (en) *	1998-10-01	2008-09-04	Elan Pharma International, Ltd.	Nanoparticulate statin formulations and novel statin combinations
US8236352B2 (en)	1998-10-01	2012-08-07	Alkermes Pharma Ireland Limited	Glipizide compositions
US8293277B2 (en) *	1998-10-01	2012-10-23	Alkermes Pharma Ireland Limited	Controlled-release nanoparticulate compositions
EP1117384A1 (de) *	1998-10-01	2001-07-25	Elan Pharma International Limited	Nanopartikelformulierungen mit kontrollierter wirkstofffreisetzung
US20040013613A1 (en) *	2001-05-18	2004-01-22	Jain Rajeev A	Rapidly disintegrating solid oral dosage form
US6428814B1 (en) *	1999-10-08	2002-08-06	Elan Pharma International Ltd.	Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) *	1998-11-12	2009-04-21	Elan Pharma International Ltd.	Dry powder aerosols of nanoparticulate drugs
US6652864B1 (en)	1998-12-21	2003-11-25	Asilomar Pharmaceuticals, Inc.	Compounds for intracellular delivery of therapeutic moieties to nerve cells
EP1147879B8 (de) *	1999-01-29	2008-12-24	Takeda Pharmaceutical Company Limited	Verdichtungshammer mit beschichtungsbehandlung
WO2000053231A2 (en) *	1999-03-09	2000-09-14	Protarga, Inc.	Fatty acid-anticancer conjugates and uses thereof
US7235583B1 (en) *	1999-03-09	2007-06-26	Luitpold Pharmaceuticals, Inc.,	Fatty acid-anticancer conjugates and uses thereof
US6475984B2 (en) *	1999-04-29	2002-11-05	The Nemours Foundation	Administration of leptin
ATE415969T1 (de) *	1999-05-07	2008-12-15	Wockhardt Ltd	(s)-benzochinolizincarbonsäuren und ihre verwendung als antibakterielle mittel
AU4834200A (en) *	1999-05-10	2000-11-21	Protarga, Inc.	Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
US6197337B1 (en) *	1999-05-10	2001-03-06	Kenneth Weisman	Therapeutic uses of abarelix
US7175855B1 (en) *	1999-05-27	2007-02-13	Pfizer Inc.	Ziprasidone suspension
US20040115134A1 (en) *	1999-06-22	2004-06-17	Elan Pharma International Ltd.	Novel nifedipine compositions
JP2003507438A (ja)	1999-08-24	2003-02-25	セルゲイト，インコーポレイテッド	オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強
US6669951B2 (en) *	1999-08-24	2003-12-30	Cellgate, Inc.	Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en)	1999-08-24	2007-06-12	Cellgate, Inc.	Compositions and methods for enhancing drug delivery across and into ocular tissues
US6730293B1 (en)	1999-08-24	2004-05-04	Cellgate, Inc.	Compositions and methods for treating inflammatory diseases of the skin
WO2001017524A1 (en) *	1999-09-09	2001-03-15	Efa Sciences Llc.	Methods for treating cell proliferative disorders including cancer
US6426367B1 (en) *	1999-09-09	2002-07-30	Efa Sciences Llc	Methods for selectively occluding blood supplies to neoplasias
US6713454B1 (en) *	1999-09-13	2004-03-30	Nobex Corporation	Prodrugs of etoposide and etoposide analogs
US6380405B1 (en)	1999-09-13	2002-04-30	Nobex Corporation	Taxane prodrugs
US6541508B2 (en) *	1999-09-13	2003-04-01	Nobex Corporation	Taxane prodrugs
EP1229934B1 (de)	1999-10-01	2014-03-05	Immunogen, Inc.	Zusammensetzungen und verfahren zur behandlung von krebs mittels immunkonjugaten und chemotherapeutischen agenzien
US6383511B1 (en) *	1999-10-25	2002-05-07	Epicept Corporation	Local prevention or amelioration of pain from surgically closed wounds
US20020045606A1 (en) *	1999-12-02	2002-04-18	Reddy Satyanarayana G.	Esters of vitamin D3 and uses thereof
US6638906B1 (en)	1999-12-13	2003-10-28	Nobex Corporation	Amphiphilic polymers and polypeptide conjugates comprising same
US6380253B1 (en) *	2000-01-05	2002-04-30	Efa Sciences Llc	Method of stabilizing and potentiating the action of anti-angiogenic substances
US20020010140A1 (en)	2000-01-19	2002-01-24	Striker Gary E.	Use of pentosan polysulfate to treat certain conditions of the prostate
MXPA01009905A (es) *	2000-02-02	2003-08-20	Univ Florida State Res Found	Taxanos sustituidos con ester en c10 como agentes antitumor.
US6649632B2 (en)	2000-02-02	2003-11-18	Fsu Research Foundation, Inc.	C10 ester substituted taxanes
AR030188A1 (es)	2000-02-02	2003-08-13	Univ Florida State Res Found	Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos
US6730691B1 (en)	2000-02-10	2004-05-04	Miles A. Galin	Uses of alpha adrenergic blocking agents
US6660750B2 (en)	2000-02-15	2003-12-09	University Of Iowa Research Foundation	Flavopiridol methods and compositions for HIV therapy
US6452024B1 (en)	2000-02-22	2002-09-17	Chaichem Pharmaceuticals International	Process for extraction and purification of paclitaxel from natural sources
US20030083342A1 (en) *	2002-08-27	2003-05-01	Steele Ronald Edward	Combination of organic compounds
US20040156872A1 (en) *	2000-05-18	2004-08-12	Elan Pharma International Ltd.	Novel nimesulide compositions
AU2002222931A1 (en)	2000-07-19	2002-01-30	University Of Pittsburgh	Synthesis and biological evaluation of analogs of the antimitotic marine natural product curacin a
US7198795B2 (en) *	2000-09-21	2007-04-03	Elan Pharma International Ltd.	In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6884777B1 (en)	2000-11-14	2005-04-26	The Nemours Foundation	Method for treating respiratory distress syndrome
ATE556706T1 (de) *	2001-03-23	2012-05-15	Luitpold Pharm Inc	Fettalkohol-arzneimittel-konjugate
JP2005500988A (ja) *	2001-03-23	2005-01-13	ルイトポルド・ファーマシューティカルズ・インコーポレーテッド	脂肪族アミン薬物複合体
US20020198228A1 (en) *	2001-04-03	2002-12-26	Kaura Sita R.	Composition and method for the treatment of respiratory desease
WO2002089853A2 (en) *	2001-05-03	2002-11-14	Allergan, Inc.	Compositions having enhanced pharmacokinetic characteristics
US20020198209A1 (en) *	2001-05-03	2002-12-26	Allergan Sales Inc.	Compositions having enhanced pharmacokinetic characteristics
US7425565B2 (en) *	2002-05-09	2008-09-16	Cedars-Sinai Medical Center	Use of benzothiopenes to treat and prevent prostate cancer
CA2354471A1 (en) *	2001-07-31	2003-01-31	Florida State University Research Foundation, Inc.	C10 ester substituted taxanes
CA2354486A1 (en) *	2001-07-31	2003-01-31	Florida State University Research Foundation, Inc.	C7 ester substituted taxanes
SG129990A1 (en) *	2001-08-01	2007-03-20	Univ Florida State Res Found	C10 ester substituted taxanes
SG125889A1 (en) *	2001-08-01	2006-10-30	Univ Florida State Res Found	C7 ester subsituted taxanes
US6852737B2 (en) *	2001-08-06	2005-02-08	Recordati Ireland Limited	Crude and crystalline forms of lercanidipine hydrochloride
KR100996239B1 (ko) *	2001-09-27	2010-11-23	바-일란 유니버시티	접합된 항-정신병 약물 및 그의 용도
US7544681B2 (en)	2001-09-27	2009-06-09	Ramot At Tel Aviv University Ltd.	Conjugated psychotropic drugs and uses thereof
AU2004201240B2 (en) *	2001-09-27	2008-08-07	Bar Ilan University	Conjugated Psychotropic Drugs and Uses Thereof
US6730667B2 (en) *	2001-11-26	2004-05-04	William R. Deagle	Iontophoresis disc pain blocker
WO2003045334A2 (en) *	2001-11-29	2003-06-05	Sound Pharmaceuticals Incorporated	Methods and compositions for ameliorating the undesirable effects of chemotherapy
WO2003057207A1 (en) *	2002-01-04	2003-07-17	Sound Pharmaceuticals Incorporated	Methods for treating hearing loss
US20040101566A1 (en) *	2002-02-04	2004-05-27	Elan Pharma International Limited	Novel benzoyl peroxide compositions
ATE464880T1 (de)	2002-02-04	2010-05-15	Elan Pharma Int Ltd	Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
US20050084489A1 (en) *	2002-03-04	2005-04-21	Wilder Ronald L.	Methods of preventing or treating disorders by administering and integrin alphanubeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
JPWO2003094917A1 (ja) *	2002-05-13	2005-09-08	高田製薬株式会社	ビントペロール含有経皮投与用医薬組成物
US20040266776A1 (en) *	2003-06-25	2004-12-30	Gil Daniel W.	Methods of preventing and reducing the severity of stress-associated conditions
US20040002663A1 (en) *	2002-06-26	2004-01-01	Reeves William H.	Method and system for use in detecting a cancerous and precancerous pathology
US20040258757A1 (en) *	2002-07-16	2004-12-23	Elan Pharma International, Ltd.	Liquid dosage compositions of stable nanoparticulate active agents
US20040023935A1 (en) *	2002-08-02	2004-02-05	Dey, L.P.	Inhalation compositions, methods of use thereof, and process for preparation of same
US7273889B2 (en) *	2002-09-25	2007-09-25	Innovative Drug Delivery Systems, Inc.	NMDA receptor antagonist formulation with reduced neurotoxicity
AU2003291634A1 (en) *	2002-10-08	2004-05-04	Sepracor Inc.	Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
US20040109826A1 (en) *	2002-12-06	2004-06-10	Dey, L.P.	Stabilized albuterol compositions and method of preparation thereof
AU2003296937A1 (en) *	2002-12-10	2004-06-30	Biosynexus Incorporated	Topical anti-infective formulations
US7524515B2 (en) *	2003-01-10	2009-04-28	Mutual Pharmaceuticals, Inc.	Pharmaceutical safety dosage forms
WO2004062620A2 (en) *	2003-01-13	2004-07-29	Cedars-Sinai Medical Center	Paricalcitol as a chemotherapeutic agent
US6759539B1 (en)	2003-02-27	2004-07-06	Chaichem Pharmaceuticals International	Process for isolation and purification of paclitaxel from natural sources
US9808471B2 (en) *	2003-04-16	2017-11-07	Mylan Specialty Lp	Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en)	2003-04-16	2014-12-16	Mylan Pharmaceuticals Inc.	Formulations and methods for treating rhinosinusitis
US7811606B2 (en) *	2003-04-16	2010-10-12	Dey, L.P.	Nasal pharmaceutical formulations and methods of using the same
NZ564694A (en) *	2003-04-22	2009-11-27	Sod Conseils Rech Applic	Peptide vectors
JP5069463B2 (ja)	2003-04-25	2012-11-07	ギリアードサイエンシーズ，インコーポレイテッド	抗ウイルス性ホスホネート類似物
US20040242655A1 (en) *	2003-05-28	2004-12-02	Anziano Paul Q.	Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
US20060089374A1 (en) *	2003-07-17	2006-04-27	Glenn Cornett	Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
GB2419529B (en) *	2003-07-17	2008-01-09	Cotherix Inc	Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
US20050187278A1 (en) *	2003-08-28	2005-08-25	Pharmacia Corporation	Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
WO2005021039A1 (en) *	2003-08-29	2005-03-10	Cotherix, Inc.	Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome
US20050148534A1 (en) *	2003-09-22	2005-07-07	Castellino Angelo J.	Small molecule compositions and methods for increasing drug efficiency using compositions thereof
GB0322994D0 (en) *	2003-10-01	2003-11-05	Novartis Ag	Organic compounds
BRPI0415858A (pt) *	2003-10-29	2007-01-09	Sonus Pharma Inc	compostos de medicamentos terapêuticos modificados por tocoferol
US20080045559A1 (en) *	2003-10-29	2008-02-21	Sonus Pharmaceuticals, Inc.	Tocopherol-modified therapeutic drug compounds
JP4884228B2 (ja) *	2003-10-30	2012-02-29	ザリサーチファウンデーションオブステイトユニバーシティオブニューヨーク	タキソイド−脂肪酸コンジュゲート及びその医薬組成物
GB0326180D0 (en) *	2003-11-11	2003-12-17	Leuven K U Res & Dev	Biocompatible coating of medical devices
HN2005000054A (es)	2004-02-13	2009-02-18	Florida State University Foundation Inc	Taxanos sustituidos con esteres de ciclopentilo en c10
TW200540164A (en)	2004-03-05	2005-12-16	Univ Florida State Res Found	C7 lactyloxy-substituted taxanes
US20100028339A1 (en)	2004-03-29	2010-02-04	Cheng Jin Q	Compositions including triciribine and trastuzumab and methods of use thereof
US20100009929A1 (en)	2004-03-29	2010-01-14	Cheng Jin Q	Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100009928A1 (en) *	2004-03-29	2010-01-14	Cheng Jin Q	Compositions including triciribine and taxanes and methods of use thereof
MXPA06011219A (es)	2004-03-29	2007-05-08	Univ South Florida	Tratamiento efectivo de tumores y cancer con triciribina y compuestos relacionados.
US20110008327A1 (en) *	2004-03-29	2011-01-13	Cheng Jin Q	Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100173864A1 (en)	2004-03-29	2010-07-08	Cheng Jin Q	Compositions including triciribine and one or more platinum compounds and methods of use thereof
GB0413729D0 (en) *	2004-06-18	2004-07-21	Tillotts Pharma Ag	A pharmaceutical composition and its use
GB0413730D0 (en) *	2004-06-18	2004-07-21	Tillotts Pharma Ag	A pharmaceutical composition and its use
ME01945B (me)	2004-07-27	2011-12-31	Gilead Sciences Inc	Nukleozid-fosfonatni konjugati kao sredstva protiv hiv-a
US20060154959A1 (en) *	2005-01-13	2006-07-13	Navitas Pharma	Combination therapies of cicletanine and carvedilol
US9132135B2 (en) *	2004-09-24	2015-09-15	University Of Maryland, Baltimore	Method of treating organophosphorous poisoning
CA2583439C (en) *	2004-09-24	2016-05-10	University Of Maryland, Baltimore	Method of treating organophosphorous poisoning
WO2006055854A2 (en) *	2004-11-17	2006-05-26	Cypress Bioscience, Inc.	Methods for reducing the side effects associated with mirtazapine treatment
US20070141174A1 (en) *	2005-01-13	2007-06-21	Navitas Pharma, Inc.	Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20080096915A1 (en) *	2005-01-13	2008-04-24	Greenberg Traurig LLP	Compositions for the treatment of metabolic disorders
CA2596755C (en)	2005-02-09	2014-09-09	Paul Q. Anziano	Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
EP1855662A4 (de) *	2005-03-08	2009-12-23	Sound Pharmaceuticals Inc	Verfahren und zusammensetzungen zur behandlung von krebs
US20060216767A1 (en) *	2005-03-22	2006-09-28	Saladax Biomedical Inc.	Docetaxel immunoassay
AU2006242914B2 (en)	2005-05-04	2012-02-02	Pronova Biopharma Norge As	New DHA derivatives and their use as medicaments
ES2400772T3 (es) *	2005-06-07	2013-04-12	Ramot At Tel Aviv University Ltd.	Sales novedosas de fármacos psicotrópicos conjugados y procedimientos para la preparación de las mismas
US20070105817A1 (en) *	2005-11-09	2007-05-10	Jim Page	Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
CN1870631B (zh) *	2005-11-11	2010-04-14	华为技术有限公司	媒体网关的门控方法
WO2007059019A2 (en) *	2005-11-14	2007-05-24	Winch Peter D	Novel colored solutions of injectable drugs and their pharmaceutically acceptable salts
CA2632149C (en) *	2005-12-01	2011-11-15	Pfizer Products Inc.	Pyrimidine derivatives for the treatment of abnormal cell growth
TW201434835A (zh)	2005-12-13	2014-09-16	Incyte Corp	作為傑納斯激酶（ＪＡＮＵＳＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
CZ300305B6 (cs) *	2005-12-20	2009-04-15	Heaton, A. S.	Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
US20100022568A1 (en) *	2006-04-13	2010-01-28	Actelion Pharmaceeuticals Ltd.	Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
CA2649895C (en) *	2006-04-19	2013-03-26	Novadel Pharma Inc.	Stable hydroalcoholic oral spray formulations and methods
EP2020996B1 (de) *	2006-05-16	2011-11-23	Gilead Sciences, Inc.	Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
FR2902659A1 (fr)	2006-06-23	2007-12-28	Pierre Fabre Medicament Sa	Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
WO2008010223A2 (en)	2006-07-17	2008-01-24	Ramot At Tel Aviv University Ltd.	Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders
WO2008014456A2 (en) *	2006-07-28	2008-01-31	Collegium Pharmaceutical, Inc.	Combination therapy for otitis with antiseptic and ph adjustment
WO2008021242A2 (en) *	2006-08-10	2008-02-21	The Research Foundation Of State University Of New York	Fluorotaxoid-fatty acid conjugates and pharmaceutical compositions thereof
US20080051380A1 (en)	2006-08-25	2008-02-28	Auerbach Alan H	Methods and compositions for treating cancer
KR101438177B1 (ko)	2006-11-01	2014-09-05	프로노바 바이오파마 너지 에이에스	페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질
DK2125786T3 (da) *	2006-12-21	2011-05-09	Pfizer Prod Inc	Succinatsalt af 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl) phenoxy)methyl) quinolin
WO2008079295A1 (en) *	2006-12-22	2008-07-03	Novadel Pharma Inc.	Stable anti-nausea oral spray formulations and methods
US20080312241A1 (en) *	2007-01-03	2008-12-18	Gilead Sciences, Inc.	Cicletanine and PKC inhibitors in the treatment of pulmonary and cardiac disorders
TWI384986B (zh) *	2007-01-17	2013-02-11	Lg Life Sciences Ltd	抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物
AU2008226645B2 (en) *	2007-03-09	2012-09-20	Novartis Ag	Salts of 3- (1H-ind0l-3-yl) -4- [2- (4-methyl-piperazin-i-yl) -quinazolin-4-yl] -pyrrole-2, 5-di one
US9220837B2 (en) *	2007-03-19	2015-12-29	Insuline Medical Ltd.	Method and device for drug delivery
BRPI0811430A2 (pt) *	2007-05-10	2015-06-23	Novadel Pharma Inc	Composições anti-insônia e processos
WO2008150845A1 (en) *	2007-05-31	2008-12-11	Vanderbilt University	Screening for wnt pathway modulators and pyrvinium for the treatment of cance
LT3070090T (lt)	2007-06-13	2019-06-25	Incyte Holdings Corporation	Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas
US8067632B2 (en)	2007-07-26	2011-11-29	The Board Of Trustees Of The Leland Stanford Junior University	Process to produce prostratin and structural or functional analogs thereof
KR20100072230A (ko) *	2007-09-26	2010-06-30	마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티	아자시티딘 유사체 및 이의 용도
US7985325B2 (en) *	2007-10-30	2011-07-26	Novellus Systems, Inc.	Closed contact electroplating cup assembly
CN101328159B (zh) *	2007-11-05	2011-12-21	孙汉翔	紫杉烷前体抗癌药及其药物组合物和用途
AU2008334924A1 (en) *	2007-12-12	2009-06-18	Ultimorphix Technolgies B.V.	Solid forms of Tenofovir disoproxil
PE20091156A1 (es) *	2007-12-17	2009-09-03	Astrazeneca Ab	Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
EP2252578B1 (de)	2008-02-11	2012-08-01	Ramot at Tel Aviv University Ltd.	Konjugate zur behandlung neurodegenerativer erkrankungen und leiden
WO2009145981A1 (en)	2008-03-31	2009-12-03	Florida State University Research Foundation, Inc.	C(10) ethyl ester and c(10) cyclopropyl ester substituted taxanes
AU2009234127B2 (en) *	2008-04-10	2015-04-30	Abraxis Bioscience, Llc	Compositions of hydrophobic taxane derivatives and uses thereof
JP5739802B2 (ja) *	2008-05-13	2015-06-24	アストラゼネカアクチボラグ	４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
US8835506B2 (en)	2008-06-05	2014-09-16	Stc.Unm	Methods and related compositions for the treatment of cancer
US8658617B2 (en) *	2008-07-08	2014-02-25	Gilead Sciences, Inc.	Salts of HIV inhibitor compounds
US9085527B2 (en)	2008-07-08	2015-07-21	Catabasis Pharmaceuticals, Inc.	Fatty acid acylated salicylates and their uses
EP2813486B1 (de)	2008-07-08	2017-10-25	Catabasis Pharmaceuticals, Inc.	Fettsäureacetylierte Salicylate und ihre Verwendungen
SG10201902903RA (en) *	2008-12-01	2019-05-30	Oyster Point Pharma Inc	Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
US9145396B2 (en)	2008-12-01	2015-09-29	Targacept, Inc.	Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
EP2375900B1 (de) *	2008-12-11	2016-03-02	Biovista, Inc.	Verfahren zur behandlung von multipler sklerose mit tetracyclischen pyrazinoindolen
BRPI0923176B8 (pt) *	2008-12-18	2021-05-25	Novartis Ag	forma cristalina do sal de hemifumarato de ácido 1-(4-{1-[(e)- 4-ciclo-hexil-3-trifluormetil-benzilóxi-imino]-etil}-2- etil-benzil)-azetidina-3-carboxílico e composição farmaceutica
US8993625B2 (en) *	2009-03-11	2015-03-31	Stable Solutions Llc	Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US9034389B2 (en)	2009-03-11	2015-05-19	Stable Solutions Llc	Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
CN102458112A (zh) *	2009-04-10	2012-05-16	阿布拉科斯生物科学有限公司	纳米颗粒制剂及其用途
SG10201402346UA (en) *	2009-05-19	2014-10-30	Vivia Biotech Sl	Methods for providing personalized medicine tests ex vivo for hematological neoplasms
PT2432472T (pt)	2009-05-22	2019-12-09	Incyte Holdings Corp	3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- ou heptano-nitrilo como inibidores de jak
WO2011028685A1 (en) *	2009-09-01	2011-03-10	Incyte Corporation	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
BR112012013639A2 (pt)	2009-12-09	2017-04-04	Bar-Ilan Univ	"métodos pára melhorar funções congnitivas"
NZ601698A (en) *	2010-01-08	2015-04-24	Catabasis Pharmaceuticals Inc	Fatty acid fumarate derivatives and their uses
EP2545045B1 (de)	2010-03-10	2016-01-06	Incyte Holdings Corporation	Piperidin-4-yl azetidinderivate als jak1-inhibitoren
EA035981B1 (ru)	2010-05-21	2020-09-09	Инсайт Холдингс Корпорейшн	Композиция ингибитора jak для местного применения
US8916610B2 (en)	2010-09-22	2014-12-23	Ramot At Tel-Aviv University Ltd.	Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
TW201249845A (en)	2010-11-19	2012-12-16	Incyte Corp	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
WO2012068440A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
US20120178813A1 (en)	2011-01-12	2012-07-12	Thetis Pharmaceuticals Llc	Lipid-lowering antidiabetic agent
WO2012154554A1 (en) *	2011-05-06	2012-11-15	Catabasis Pharmaceuticals, Inc.	Fatty acid triterpene derivatives and their uses
ES2560611T3 (es)	2011-06-20	2016-02-22	Incyte Holdings Corporation	Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK
CN102952138B (zh) *	2011-08-17	2016-07-06	上海特化医药科技有限公司	一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
SI2915525T1 (sl)	2011-09-19	2022-01-31	Orexo Ab	Sublingvalne tablete, odporne proti zlorabi, ki vsebujejo buprenorfin in nalokson
EP2847158A4 (de) *	2012-05-07	2015-12-30	Cellix Bio Private Ltd	Zusammensetzungen und verfahren zur behandlung neuromuskulärer erkrankungen und neurodegenerativer erkrankungen
TW201406761A (zh)	2012-05-18	2014-02-16	Incyte Corp	做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
US8765811B2 (en)	2012-07-10	2014-07-01	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
US9382187B2 (en)	2012-07-10	2016-07-05	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
CN105007901A (zh)	2012-11-15	2015-10-28	因赛特公司	鲁索利替尼的缓释剂型
TWI634121B (zh)	2013-03-06	2018-09-01	英塞特控股公司	用於製備ｊａｋ抑制劑之方法及中間物
TWI822248B (zh)	2013-08-07	2023-11-11	美商英塞特控股公司	Jak1抑制劑之持續釋放劑型
US10463684B2 (en)	2014-01-29	2019-11-05	Board Of Regents, The Uneversety Of Texas System	Nucleobase analogue derivatives and their applications
CA2947741A1 (en)	2014-05-05	2015-11-12	Thetis Pharmaceuticals Llc	Compositions and methods relating to ionic salts of peptides
US9498467B2 (en)	2014-05-30	2016-11-22	Incyte Corporation	Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9999626B2 (en)	2014-06-18	2018-06-19	Thetis Pharmaceuticals Llc	Mineral amino-acid complexes of active agents
US9242008B2 (en)	2014-06-18	2016-01-26	Thetis Pharmaceuticals Llc	Mineral amino-acid complexes of fatty acids
CN104225615B (zh) *	2014-09-24	2017-02-01	东南大学	一种紫杉醇类磷脂化合物、其药物组合物及应用
WO2016198971A1 (en) *	2015-06-08	2016-12-15	Mohan M Alapati	Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
WO2017160687A1 (en) *	2016-03-15	2017-09-21	Vitality Biopharma, Inc.	Methods and compositions for the treatment of demyelinating disorders
ES2827796T3 (es)	2016-06-03	2021-05-24	Thetis Pharmaceuticals Llc	Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
EP3960740B1 (de)	2017-08-01	2023-11-15	Gilead Sciences, Inc.	Kristalline formen von ethyl((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluor-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninat (gs-9131) vanillate zur behandlung von virusinfektionen
US10596161B2 (en)	2017-12-08	2020-03-24	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
MD3746429T2 (ro)	2018-01-30	2022-08-31	Incyte Corp	Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
CN113768927A (zh)	2018-03-30	2021-12-10	因赛特公司	使用jak抑制剂治疗化脓性汗腺炎
KR20210002541A (ko) *	2018-04-17	2021-01-08	카듀리온 파마슈티칼스, 인크.	티에노피리미딘의 메글루민 염
JP2021530507A (ja)	2018-07-18	2021-11-11	マンザニータファーマシューティカルズ，インク．	神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法
US11643438B2 (en)	2018-07-20	2023-05-09	The Board Of Regents Of The University Of Oklahoma	Antimicrobial peptides and methods of use
WO2020023910A1 (en)	2018-07-26	2020-01-30	Tolero Pharmaceuticals, Inc.	Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
EP3941897A4 (de) *	2019-03-22	2023-04-05	Integrated Nanotherapeutics Inc.	Aus einem gerüstteil hergestelltes lipidkonjugat
EP4061367A1 (de)	2019-11-22	2022-09-28	Incyte Corporation	Kombinationstherapie, die einen alk2-inhibitor und einen jak2-inhibitor umfasst
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US449A (en) *		1837-11-11		Improvement in the mode of preparing paint for the protection of buildings against fire
US3539573A (en) *	1967-03-22	1970-11-10	Jean Schmutz	11-basic substituted dibenzodiazepines and dibenzothiazepines
US3621048A (en) *	1968-03-14	1971-11-16	Colgate Palmolive Co	Quaternary ammonium compounds
US4218234A (en) *	1972-12-07	1980-08-19	Novex Rt.	Soil conditioners
SU477159A1 (ru)	1973-07-27	1975-07-15	Всесоюзный научно-исследовательский институт фитопатологии	Способ получени амидофосфорилоксиэтиламидов карбоновых кислот
JPS5186479A (en)	1975-01-22	1976-07-29	Asahi Chemical Ind	55 furuororashirujudotainoseizohoho
FR2298332A1 (fr)	1975-01-22	1976-08-20	Asahi Chemical Ind	Nouveaux derives de 5-fluorouraciles
US4097597A (en) *	1977-02-23	1978-06-27	Abbott Laboratories	Dibenzo b,e! 1,4!diazepines
US4351831A (en) *	1977-11-02	1982-09-28	Massachusetts Institute Of Technology	Process and composition for treating disorders by administering isoxsurpine and choline
US4407744A (en)	1977-11-23	1983-10-04	Young David M	Process for obtaining nerve growth factor
US4287184A (en)	1977-11-23	1981-09-01	The Massachusetts General Hospital	Process for healing wounds
US4185095A (en)	1977-11-23	1980-01-22	The Massachusetts General Hospital	Nerve growth factor
JPS5553208A (en)	1978-10-13	1980-04-18	Mitsubishi Chem Ind Ltd	Insecticide
IT7927748A0 (it) *	1979-11-30	1979-11-30	Simes	Derivati dell'acido 6,6'-diapopsi psicarotenedioico e relativi procedimenti di preparazione.
US4346085A (en) *	1980-02-29	1982-08-24	Massachusetts Institute Of Technology	Process and composition for treating disorders by administering amphetamine and choline
US4636494A (en) *	1981-01-30	1987-01-13	Massachusetts Institute Of Technology	Process and composition for treating disorders by administering amphetamine and choline
JPS58177953A (ja) *	1982-04-13	1983-10-18	Eisai Co Ltd	ポリプレニルカルボン酸アミドおよびその製造方法
JPS5925327A (ja)	1982-07-31	1984-02-09	Hidematsu Hirai	抗腫瘍性複合体の製造方法
US4558049A (en)	1982-11-24	1985-12-10	Farmitalia Carlo Erba S.P.A.	Antipsycotic benzoxazines
US5169762A (en)	1983-03-03	1992-12-08	Genentech, Inc.	Human nerve growth factor by recombinant technology
JPS59204175A (ja)	1983-04-28	1984-11-19	Terumo Corp	５―フルオロウラシル誘導体を有効成分とする血小板凝集抑制剤
DE3480706D1 (de) *	1983-10-20	1990-01-18	Terumo Corp	5-fluoruracilabkoemmlinge sowie medizinische zusammensetzungen die diese enthalten.
US4550109A (en) *	1984-05-31	1985-10-29	The Board Of Regents, The University Of Texas System	Lipoidal biopterin compounds
US4684646A (en) *	1984-06-26	1987-08-04	Merck & Co., Inc.	2-acylaminomethyl-1,4-benzodiazepine derivatives as CCK-antagonists
US4868161A (en) *	1984-06-29	1989-09-19	City Of Hope	Method for promoting nerve regeneration
IL72684A (en)	1984-08-14	1989-02-28	Israel State	Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4554272A (en) *	1985-01-25	1985-11-19	Merck & Co., Inc.	Substituted quinazolino-1,4-benzodiazepin-6,9-diones and their preparation
US5223263A (en)	1988-07-07	1993-06-29	Vical, Inc.	Liponucleotide-containing liposomes
US6448392B1 (en) *	1985-03-06	2002-09-10	Chimerix, Inc.	Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US4729989A (en)	1985-06-28	1988-03-08	Merck & Co., Inc.	Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
US4692441A (en)	1985-08-16	1987-09-08	Merck & Co., Inc.	Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
US5246726A (en)	1986-03-21	1993-09-21	Efamol Ltd.	Iron-containing composition and method for treatment of cancer
FR2601676B1 (fr) *	1986-07-17	1988-09-23	Rhone Poulenc Sante	Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) *	1986-07-17	1988-09-23	Rhone Poulenc Sante	Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4902505A (en) *	1986-07-30	1990-02-20	Alkermes	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4968672A (en)	1987-01-02	1990-11-06	The United States Of America As Represented By The Department Of Health And Human Services	Adenosine receptor prodrugs
US5459256A (en)	1987-04-17	1995-10-17	The Government Of The United States Of America As Represented By The Department Of Health And Human Services	Lipophilic, aminohydrolase-activated prodrugs
SE8703625D0 (sv)	1987-09-18	1987-09-18	Kabivitrum Ab	New medical use
AU2526188A (en)	1987-09-22	1989-04-18	Regents Of The University Of California, The	Liposomal nucleoside analogues for treating aids
US4943579A (en)	1987-10-06	1990-07-24	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Water soluble prodrugs of camptothecin
US5420276A (en)	1987-11-03	1995-05-30	Abbott Laboratories	Analogs of oxetanyl purines and pyrimidines
JPH01153629A (ja)	1987-12-11	1989-06-15	Nippon Oil & Fats Co Ltd	制癌剤
JPH01203331A (ja)	1988-02-05	1989-08-16	Rikagaku Kenkyusho	制癌剤
US4939174A (en) *	1988-02-26	1990-07-03	Shashoua Victor E	Appetite suppression with dopamine-fatty acid conjugates
US5994392A (en)	1988-02-26	1999-11-30	Neuromedica, Inc.	Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US6107499A (en) *	1988-02-26	2000-08-22	Neuromedica, Inc.	Dopamine analog amide
US5284876A (en)	1988-02-26	1994-02-08	Neuromedica, Inc.	Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
US4933324A (en) *	1988-02-26	1990-06-12	Shashoua Victor E	Fatty acid-neuroactive drug conjugate as a prodrug
JPH01287022A (ja)	1988-05-12	1989-11-17	Nippon Oil & Fats Co Ltd	抗癌剤耐性克服剤
GB8813766D0 (en)	1988-06-10	1988-07-13	Efamol Holdings	Essential fatty acid compositions
US6252060B1 (en)	1988-07-07	2001-06-26	Nexstar Pharmaceuticals, Inc.	Antiviral liponucleosides: treatment of hepatitis B
JP2612619B2 (ja)	1988-12-14	1997-05-21	財団法人相模中央化学研究所	含リン化合物よりなる経皮吸収促進剤
CH676909A5 (de)	1988-12-23	1991-03-28	Nestle Sa
HU207287B (en)	1989-01-17	1993-03-29	Biosignal Kutato Fejlesztoe Kf	Polyene fatty acid derivatives of tyrozine-quinaze inhibiting activity and pharmaceutical composition containing them as active component
US5216142A (en)	1989-04-17	1993-06-01	Efamol Holdings Plc	Anti-virals
US5411947A (en) *	1989-06-28	1995-05-02	Vestar, Inc.	Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) *	1989-11-22	1993-03-16	Vical, Inc.	Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
GB8918294D0 (en)	1989-08-10	1989-09-20	Efamol Holdings	Pharmaceutical compositions
JPH03236315A (ja)	1989-12-05	1991-10-22	Nippon Oil & Fats Co Ltd	抗精神病薬
GB9001121D0 (en)	1990-01-18	1990-03-21	Efamol Holdings	Efa compositions and therapy
US5112596A (en)	1990-04-23	1992-05-12	Alkermes, Inc.	Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5545719A (en) *	1990-05-01	1996-08-13	Neuromedica, Inc.	Nerve growth peptides
JP2800953B2 (ja) *	1990-07-06	1998-09-21	住友製薬株式会社	新規なイミド誘導体
US5169764A (en)	1990-08-08	1992-12-08	Regeneron Pharmaceuticals, Inc.	Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
JP3139777B2 (ja)	1990-08-27	2001-03-05	フマキラー株式会社	組換えダニアレルゲン
US5278324A (en) *	1990-08-28	1994-01-11	Virginia Tech Intellectual Properties, Inc.	Water soluble derivatives of taxol
US5059699A (en) *	1990-08-28	1991-10-22	Virginia Tech Intellectual Properties, Inc.	Water soluble derivatives of taxol
US5827819A (en)	1990-11-01	1998-10-27	Oregon Health Sciences University	Covalent polar lipid conjugates with neurologically active compounds for targeting
MX9102128A (es) *	1990-11-23	1992-07-08	Rhone Poulenc Rorer Sa	Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
GB9108056D0 (en)	1991-04-16	1991-06-05	Hale Geoffrey	Synthetic antigen
WO1992020362A1 (en) *	1991-05-14	1992-11-26	Shashoua Victor E	Nerve growth peptides and uses therefor
US5369191A (en) *	1992-01-23	1994-11-29	Kureha Kagaku Kogyo K.K.	Aromatic thioether ketone/thioether sulfone copolymer and production process thereof
IT1254517B (it) *	1992-03-06	1995-09-25	Indena Spa	14-beta idrossi-10-deacetil-baccatina iii, suoi derivati, loro prepazione ed impiego terapeutico
IT1254515B (it) *	1992-03-06	1995-09-25	Indena Spa	Tassani di interesse oncologico, loro metodo di preparazione ed uso
US5214062A (en)	1992-04-08	1993-05-25	Clintec Nutrition Co.	Method and composition for treating immune disorders, inflammation and chronic infections
GB9213077D0 (en) *	1992-06-19	1992-08-05	Erba Carlo Spa	Polymerbound taxol derivatives
JPH0616548A (ja)	1992-06-30	1994-01-25	Sagami Chem Res Center	組織異常増殖抑制剤
DE4224737A1 (de)	1992-07-27	1994-02-03	Herbert Prof Dr Schott	Neue Cytosinnucleosidanaloga, Verfahren zu ihrer Herstellung und ihre Verwendung
US5308832A (en)	1992-07-27	1994-05-03	Abbott Laboratories	Nutritional product for persons having a neurological injury
US5352596A (en)	1992-09-11	1994-10-04	The United States Of America As Represented By The Secretary Of Agriculture	Pseudorabies virus deletion mutants involving the EPO and LLT genes
US5453521A (en) *	1992-10-05	1995-09-26	Rhone-Poulenc Rorer S.A.	Process for obtaining 10-deacetylbaccatin III
FR2696461B1 (fr) *	1992-10-05	1994-11-10	Rhone Poulenc Rorer Sa	Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
US5356928A (en) *	1992-11-06	1994-10-18	Hauser Chemical Research, Inc.	Cytotoxic agents
FR2697841B1 (fr) *	1992-11-12	1995-01-13	Rhone Poulenc Rorer Sa	Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2698269B1 (fr)	1992-11-24	1995-01-06	Inst Nat Sante Rech Med	Nouveaux médicaments à base d'acides gras insaturés, utilisables notamment comme antiagrégants plaquettaires et/ou comme transporteurs privilégiés vers le cerveau.
GB9224809D0 (en)	1992-11-26	1993-01-13	Scotia Holdings Plc	Schizophrenia
AU5574094A (en) *	1992-11-30	1994-06-22	Biosignal Kutato-Fejleszto Kft.	Polyunsaturated fatty acyl-peptide composition
US5496714A (en)	1992-12-09	1996-03-05	New England Biolabs, Inc.	Modification of protein by use of a controllable interveining protein sequence
FR2698871B1 (fr) *	1992-12-09	1995-02-24	Rhone Poulenc Rorer Sa	Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
GB9300125D0 (en)	1993-01-06	1993-03-03	Scotia Holdings Plc	Compositions containing esters of unsaturated fatty acids
GB9301629D0 (en)	1993-01-27	1993-03-17	Scotia Holdings Plc	Formulations containing unsaturated fatty acids
GB9304746D0 (en)	1993-03-09	1993-04-28	Scotia Holdings Plc	Treatment of viral infections
IL105244A (en)	1993-03-31	2003-07-31	Dpharm Ltd	Prodrugs with enhanced penetration into cells
US6413949B1 (en)	1995-06-07	2002-07-02	D-Pharm, Ltd.	Prodrugs with enhanced penetration into cells
US5643909A (en) *	1993-04-19	1997-07-01	Syntex (U.S.A.) Inc.	10,11-Methanodibenzosuberane derivatives
US5336684A (en) *	1993-04-26	1994-08-09	Hauser Chemical Research, Inc.	Oxidation products of cephalomannine
FR2707293A1 (fr) *	1993-07-08	1995-01-13	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5798340A (en)	1993-09-17	1998-08-25	Gilead Sciences, Inc.	Nucleotide analogs
TW406020B (en)	1993-09-29	2000-09-21	Bristol Myers Squibb Co	Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5824701A (en) *	1993-10-20	1998-10-20	Enzon, Inc.	Taxane-based prodrugs
FR2712289B1 (fr) *	1993-11-08	1996-01-05	Rhone Poulenc Rorer Sa	Nouveaux dérivés de taxicine, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2712288B1 (fr) *	1993-11-08	1996-01-05	Rhone Poulenc Rorer Sa	Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5480799A (en)	1993-12-10	1996-01-02	The University Of North Carolina At Chapel Hill	Sperm antigen corresponding to a sperm zona binding protein autoantigenic epitope
IT1264987B1 (it)	1993-12-14	1996-10-17	Prospa Bv	Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
US5447936A (en) *	1993-12-22	1995-09-05	Bionumerik Pharmaceuticals, Inc.	Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
GB9403857D0 (en) *	1994-03-01	1994-04-20	Scotia Holdings Plc	Fatty acid derivatives
US5925669A (en) *	1994-03-22	1999-07-20	Molecular/Structural Bio Technologies, Inc.	Carrier compositions for anti-neoplastic drugs
US5468754A (en) *	1994-04-19	1995-11-21	Bionumerik Pharmaceuticals, Inc.	11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5604198A (en) *	1994-05-12	1997-02-18	Poduslo; Joseph F.	Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US5534499A (en) *	1994-05-19	1996-07-09	The University Of British Columbia	Lipophilic drug derivatives for use in liposomes
FR2721023B1 (fr) *	1994-06-09	1996-07-12	Rhone Poulenc Rorer Sa	Nouveaux Taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
JPH0815133A (ja)	1994-06-29	1996-01-19	Hitachi Ltd	分析素子
FR2721928A1 (fr) *	1994-07-04	1996-01-05	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US5597719A (en)	1994-07-14	1997-01-28	Onyx Pharmaceuticals, Inc.	Interaction of RAF-1 and 14-3-3 proteins
JPH0827010A (ja)	1994-07-19	1996-01-30	Nichinichi Seiyaku Kk	制癌免疫療法剤
AU3275595A (en) *	1994-08-05	1996-03-04	Molecular/Structural Biotechnologies, Inc.	Site-specific biomolecular complexes
US5716614A (en)	1994-08-05	1998-02-10	Molecular/Structural Biotechnologies, Inc.	Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
JPH08163991A (ja)	1994-12-15	1996-06-25	Mitsui Petrochem Ind Ltd	タキサン型ジテルペンの製造方法
US5580899A (en)	1995-01-09	1996-12-03	The Liposome Company, Inc.	Hydrophobic taxane derivatives
JPH11502509A (ja)	1995-01-16	1999-03-02	コモンウェルスサイエンティフィックアンドインダストリアルリサーチオーガニゼーション	治療用化合物 − 脂肪酸抱合体
US5977061A (en)	1995-04-21	1999-11-02	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	N6 - substituted nucleotide analagues and their use
MY118354A (en) *	1995-05-01	2004-10-30	Scarista Ltd	1,3-propane diol derivatives as bioactive compounds
US5532374A (en) *	1995-06-06	1996-07-02	Hitachi Chemical Company, Ltd.	Method of preparation of bis-quinolines
JPH0925231A (ja)	1995-07-13	1997-01-28	Sagami Chem Res Center	癌転移抑制剤
JPH0930963A (ja)	1995-07-21	1997-02-04	Nisshin Oil Mills Ltd:The	医療用油脂含有組成物
US5952317A (en) *	1995-09-21	1999-09-14	Wisconsin Alumni Research Foundation	Calcitriol derivatives and their uses
US5646180A (en) *	1995-12-05	1997-07-08	Vertex Pharmaceuticals Incorporated	Treatment of the CNS effects of HIV
WO1997044026A1 (en) *	1996-05-22	1997-11-27	Neuromedica, Inc.	Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US5795909A (en) *	1996-05-22	1998-08-18	Neuromedica, Inc.	DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) *	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
US6576636B2 (en) *	1996-05-22	2003-06-10	Protarga, Inc.	Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5922695A (en)	1996-07-26	1999-07-13	Gilead Sciences, Inc.	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
GB9618420D0 (en) *	1996-09-04	1996-10-16	Scotia Holdings Plc	Fatty acid treatment
US5976784A (en)	1996-09-20	1999-11-02	Wisconsin Alumni Research Foundation	Calcitriol derivatives and their uses
JPH10168047A (ja)	1996-12-04	1998-06-23	Kao Corp	アミド誘導体及びこれを含有する外用剤組成物
US6197764B1 (en)	1997-11-26	2001-03-06	Protarga, Inc.	Clozapine compositions and uses thereof
US5977174A (en)	1997-11-26	1999-11-02	Neuromedica, Inc.	Cholinergic compositions and uses thereof
US5955459A (en) *	1997-11-26	1999-09-21	Neuromedica, Inc.	Fatty acid-antipsychotic compositions and uses thereof
US6153653A (en)	1997-11-26	2000-11-28	Protarga, Inc.	Choline compositions and uses thereof
US6225444B1 (en) *	1998-02-10	2001-05-01	Protarga, Inc.	Neuroprotective peptides and uses thereof
US6184164B1 (en) *	1999-04-28	2001-02-06	The University Of Houston	Bimodal silicon nitride-bas ceramic composites
US6459645B2 (en)	1999-09-30	2002-10-01	Intel Corporation	VPX bank architecture

1996
- 1996-05-22 US US08/651,312 patent/US5795909A/en not_active Expired - Lifetime
1997
- 1997-05-22 CA CA002255614A patent/CA2255614C/en not_active Expired - Fee Related
- 1997-05-22 DK DK97926723T patent/DK0909183T3/da active
- 1997-05-22 AT AT97926723T patent/ATE273025T1/de not_active IP Right Cessation
- 1997-05-22 DE DE69730217T patent/DE69730217T2/de not_active Expired - Lifetime
- 1997-05-22 ES ES97926723T patent/ES2222514T3/es not_active Expired - Lifetime
- 1997-05-22 WO PCT/US1997/008867 patent/WO1997044063A2/en active IP Right Grant
- 1997-05-22 EP EP97926723A patent/EP0909183B1/de not_active Expired - Lifetime
- 1997-05-22 AU AU31425/97A patent/AU725759B2/en not_active Ceased
- 1997-05-22 EP EP04015625A patent/EP1466628A1/de not_active Withdrawn
- 1997-05-22 JP JP54281197A patent/JP4402173B2/ja not_active Expired - Fee Related
2001
- 2001-05-01 US US09/846,838 patent/US6602902B2/en not_active Expired - Lifetime
2003
- 2003-07-14 US US10/618,884 patent/US7199151B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ATE273025T1 (de)	2004-08-15
AU3142597A (en)	1997-12-09
CA2255614C (en)	2009-12-15
US5795909A (en)	1998-08-18
DK0909183T3 (da)	2004-12-20
EP1466628A1 (de)	2004-10-13
WO1997044063A3 (en)	1998-02-26
US7199151B2 (en)	2007-04-03
US20040180949A1 (en)	2004-09-16
JP4402173B2 (ja)	2010-01-20
EP0909183A2 (de)	1999-04-21
EP0909183B1 (de)	2004-08-11
CA2255614A1 (en)	1997-11-27
AU725759B2 (en)	2000-10-19
DE69730217T2 (de)	2005-07-28
JP2000514405A (ja)	2000-10-31
ES2222514T3 (es)	2005-02-01
WO1997044063A2 (en)	1997-11-27
US20020010208A1 (en)	2002-01-24
US6602902B2 (en)	2003-08-05

Legal Events

Date	Code	Title	Description
2005-05-19	8327	Change in the person/name/address of the patent owner	Owner name: LUITPOLD PHARMACEUTICALS, INC., SHIRLEY, N.Y., US
2005-09-08	8364	No opposition during term of opposition

Publication	Publication Date	Title
DE69730217D1 (de)	2004-09-16	Dha-pharmazeutisches produkt konjugate
DE69830336D1 (de)	2005-06-30	Ein kovalentes konjugat von clozapine und einer fettsäure und dessen verwendung zur behandlung von schizophrenie
IL132398A0 (en)	2001-03-19	Piperazine derivatives and their use as anti-inflammatory agents
PT1075282E (pt)	2005-09-30	Conjugados analogos de peg-lhrh
DE69625518D1 (de)	2003-01-30	Wirkstoff zur behandlung neurodegenerativer störungen
TR199903331T2 (xx)	2000-06-21	Farnesil protein transferas engelleyicileri.
DE69703294T2 (de)	2001-05-17	Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
BE2013C033I2 (de)	2019-10-16
BR9506820A (pt)	1997-09-09	Derivados de 4-amino de ácido micofenólico
DE69708100D1 (de)	2001-12-13	Konjugate von cis-docosahexaensäure und paclitaxel
DE69910216D1 (de)	2003-09-11	Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung
ATE406382T1 (de)	2008-09-15	Tropoelastinderivate
PH31406A (en)	1998-10-29	6-Substituted mycophenolic acid and derivatives.
FR2687681B1 (fr)	1995-10-13	Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
GB9509888D0 (en)	1995-07-12	Terpenoidic derivatives useful as antitumour agents
DE69835828D1 (de)	2006-10-19	Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression
BR9710992A (pt)	2000-10-24	Derivados anticovulsivos úteis no tratamento de psorìase
ES2159087T3 (es)	2001-09-16	Oxindoles sustituidos con adamantilo como agentes farmaceuticos.
GEU1998402Y (en)	1998-11-30	Means for Treatment of Skin Cancer - “Khvedelidze Ointment”
FR2715658B1 (fr)	1996-03-22	Dérivés de N-(3-aminopropyl)-N-phényl-5,6,7,8-tétrahydronaphtalène-2-carboxamide, leur préparation et leur application en thérapeutique.